Recruitment

Recruitment Status
Recruiting
Estimated Enrollment
200

Summary

Conditions
  • Carcinoma Non-small-cell Lung
  • Carcinoma, Squamous Cell of Head and Neck
  • Colorectal Neoplasms
  • Exocrine Pancreatic Cancer
Type
Interventional
Phase
Phase 2
Design
Allocation: Non-RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Description

The primary goal of this trial is to assess the activity, safety, and tolerability of tisotumab vedotin for the treatment of selected solid tumors. Patients will be treated with single agent tisotumab vedotin. Patients who meet eligibility criteria will be enrolled into cohorts based on tumor type. ...

The primary goal of this trial is to assess the activity, safety, and tolerability of tisotumab vedotin for the treatment of selected solid tumors. Patients will be treated with single agent tisotumab vedotin. Patients who meet eligibility criteria will be enrolled into cohorts based on tumor type. Tumor types to be evaluated include colorectal cancer, squamous non-small cell lung cancer (NSCLC), exocrine pancreatic adenocarcinoma, and squamous cell carcinoma of the head and neck (SCCHN).

Tracking Information

NCT #
NCT03485209
Collaborators
Genmab
Investigators
Study Director: Francisco Beca, MD, PhD Seagen Inc.